Your browser doesn't support javascript.
loading
Branched-chain amino acids and type 2 diabetes: a bidirectional Mendelian randomization analysis.
Mosley, Jonathan D; Shi, Mingjian; Agamasu, David; Vaitinadin, Nataraja Sarma; Murthy, Venkatesh L; Shah, Ravi V; Bagheri, Minoo; Ferguson, Jane F.
Afiliação
  • Mosley JD; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Shi M; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Agamasu D; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Vaitinadin NS; Meharry Medical College, Nashville, Tennessee, USA.
  • Murthy VL; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Shah RV; Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Bagheri M; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Ferguson JF; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Obesity (Silver Spring) ; 32(2): 423-435, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38269471
ABSTRACT

OBJECTIVE:

Genetic studies have suggested that the branched-chain amino acids (BCAAs) valine, leucine, and isoleucine have a causal association with type 2 diabetes (T2D). However, inferences are based on a limited number of genetic loci associated with BCAAs.

METHODS:

Instrumental variables (IVs) for each BCAA were constructed and validated using large well-powered data sets and their association with T2D was tested using a two-sample inverse-variance weighted Mendelian randomization approach. Sensitivity analyses were performed to ensure the accuracy of the findings. A reverse association was assessed using instrumental variables for T2D.

RESULTS:

Estimated effect sizes between BCAA IVs and T2D, excluding outliers, were as follows valine (ß = 0.14 change in log-odds per SD change in valine, 95% CI -0.06 to 0.33, p = 0.17), leucine (ß = 0.15, 95% CI -0.02 to 0.32, p = 0.09), and isoleucine (ß = 0.13, 95% CI -0.08 to 0.34, p = 0.24). In contrast, T2D IVs were positively associated with each BCAA, i.e., valine (ß = 0.08 per SD change in levels per log-odds change in T2D, 95% CI 0.05 to 0.10, p = 1.8 × 10-9 ), leucine (ß = 0.06, 95% CI 0.04 to 0.09, p = 4.5 × 10-8 ), and isoleucine (ß = 0.06, 95% CI 0.04 to 0.08, p = 2.8 × 10-8 ).

CONCLUSIONS:

These data suggest that the BCAAs are not mediators of T2D risk but are biomarkers of diabetes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Aminoácidos de Cadeia Ramificada Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Aminoácidos de Cadeia Ramificada Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article